PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30663092-4 2019 So the radiosynthesis of a fluorine-18-labelled COX-2 inhibitor [18 F]1b, a close derivative of valdecoxib, was performed with 18 FBIC and 1-ethynyl-4-(methylsulfonyl)benzene, providing [18 F]1b in up to 40% RCY after purification in 85 minutes. valdecoxib 96-106 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 30108944-0 2018 Novel valdecoxib derivatives by ruthenium(ii)-promoted 1,3-dipolar cycloaddition of nitrile oxides with alkynes - synthesis and COX-2 inhibition activity. valdecoxib 6-16 mitochondrially encoded cytochrome c oxidase II Homo sapiens 128-133 29502024-1 2018 Herein we report the synthesis of a new series of aromatic sulfamates designed considering the sulfonamide COX-2 selective inhibitors celecoxib and valdecoxib as lead compounds. valdecoxib 148-158 mitochondrially encoded cytochrome c oxidase II Homo sapiens 107-112 30288211-0 2018 Correction: Novel valdecoxib derivatives by ruthenium(ii)-promoted 1,3-dipolar cycloaddition of nitrile oxides with alkynes - synthesis and COX-2 inhibition activity. valdecoxib 18-28 mitochondrially encoded cytochrome c oxidase II Homo sapiens 140-145 26183281-7 2015 Moreover, secretion of PGE2 was considerably reduced by treatment with the COX-2 inhibitor Valdecoxib, demonstrating the functional utility of our newly established monolayer for preclinical therapeutic assays. valdecoxib 91-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 26982261-3 2017 Celecoxib, rofecoxib, and valdecoxib are well-known specific COX-2 inhibiting drugs. valdecoxib 26-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 27354402-4 2017 In this study, we have hypothesized that COX-2 specific inhibitors such as Valdecoxib (VLX), being highly hydrophobic, may alter biophysical properties of cellular lipids. valdecoxib 75-85 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 27354402-4 2017 In this study, we have hypothesized that COX-2 specific inhibitors such as Valdecoxib (VLX), being highly hydrophobic, may alter biophysical properties of cellular lipids. valdecoxib 87-90 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 25770423-7 2015 However, treatment with celecoxib or another COX-2 selective inhibitor (valdecoxib) completely blocked radiation-induced increase of PTEN phosphorylation, rescued radiation-induced decrease in PTEN membrane translocation, and correspondingly inactivated AKT. valdecoxib 72-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 27537326-6 2016 Increasing COX-2 drug selectivity, as for rofecoxib, valdecoxib, parecoxib, and lumiracoxib, has been associated with higher cardiovascular risk, as well as dermatological and serious hepatic reactions. valdecoxib 53-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 11-16 26130144-21 2015 Since a study of a selective COX-2 inhibitor NSAID (valdecoxib) that was subsequently withdrawn from the market dominates the evidence for this comparison (706 participants included in the analyses for pain, function and gastrointestinal adverse events), the applicability of these results is in doubt and we give only a brief summary. valdecoxib 52-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 25946000-10 2015 Among the 9 drugs, 4 drugs (diflunisal, nabumetone, niflumic acid and valdecoxib) targeting COX2 (prostaglandin G/H synthase 2) were repurposed for treating type 1 diabetes, and 2 drugs (phenoxybenzamine and idazoxan) targeting ADRA2A (Alpha-2A adrenergic receptor) had a new indication for treating type 2 diabetes. valdecoxib 70-80 mitochondrially encoded cytochrome c oxidase II Homo sapiens 92-96 24570829-1 2013 OBJECTIVE(S): Nowadays, COX - 2 inhibitors such as valdecoxib are removed from the market because of their cardiovascular toxicity and their potential to increase the risk of strokes. valdecoxib 51-61 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-31 23984829-0 2014 Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization. valdecoxib 59-69 mitochondrially encoded cytochrome c oxidase II Homo sapiens 16-21 23984829-2 2014 This study presents 16 analogs of lumiracoxib and 10 analogs to valdecoxib having properties suitable as COX-2 inhibitors. valdecoxib 64-74 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110 24365321-21 2014 Selective inhibition of COX-2 by drugs such as rofecoxib (Vioxx) and valdecoxib (Bextra) results in specific inhibition of synthesis of prostaglandins participating in inflammation and was found to lead to vascular complications including an increased risk for stroke. valdecoxib 69-79 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 24365321-21 2014 Selective inhibition of COX-2 by drugs such as rofecoxib (Vioxx) and valdecoxib (Bextra) results in specific inhibition of synthesis of prostaglandins participating in inflammation and was found to lead to vascular complications including an increased risk for stroke. valdecoxib 81-87 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 24431307-3 2013 OBJECTIVES: The aim of this study was to check whether valdecoxib - a selective COX-2 inhibitor - inhibits VEGF and/or bFGF secretion in the presence of LPS or cobalt chloride in normal human microvascular endothelial cells (HMEC-1). valdecoxib 55-65 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 22130459-1 2012 Parecoxib is an inactive pro-drug that is rapidly converted to valdecoxib, a selective cyclooxygenase (COX)-2 inhibitor registered for the management of post-operative pain in humans. valdecoxib 63-73 mitochondrially encoded cytochrome c oxidase II Homo sapiens 87-109 18171312-1 2008 Valdecoxib is an NSAID that is selective for COX-2 (commonly named coxibs). valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 18802217-2 2008 This may hold true for other systems because long term use of selective COX-2 inhibitors such as VIOXX and BEXTRA was associated with heart failure, leading to their withdrawal. valdecoxib 107-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 72-77 18171312-4 2008 Similarly to other coxibs and some traditional (t)NSAIDs less selective for COX-2, such as diclofenac, valdecoxib may increase the risk of thrombotic events through a prostacyclin-based mechanism. valdecoxib 103-113 mitochondrially encoded cytochrome c oxidase II Homo sapiens 76-81 20699408-5 2010 It was synthesized as an analog of the known COX-2 inhibitor valdecoxib (4-[5-methyl-3-phenyl-4-isoxazolyl]-benzenesulfonamide) (Talley et al., 2000). valdecoxib 61-71 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 20699408-5 2010 It was synthesized as an analog of the known COX-2 inhibitor valdecoxib (4-[5-methyl-3-phenyl-4-isoxazolyl]-benzenesulfonamide) (Talley et al., 2000). valdecoxib 73-126 mitochondrially encoded cytochrome c oxidase II Homo sapiens 45-50 20699408-6 2010 N-Hydroxy-valdecoxib had low in vitro COX-2 activity but showed significant analgesic activity in vivo and a prolonged therapeutic effect compared with valdecoxib (Erdelyi et al., 2008). valdecoxib 10-20 mitochondrially encoded cytochrome c oxidase II Homo sapiens 38-43 19563267-6 2009 CONCLUSION: Structural analogues of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole and thione derivatives emerge as promising leads for the treatment of inflammation, pain and other diseases. valdecoxib 71-81 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 19578771-1 2009 Valdecoxib is a second generation selective COX-2 inhibitor that can induce cell apoptosis in a variety of cell types, but its precise regulatory mechanism is unknown. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 18353655-2 2008 N-Hydroxy-4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide (3)-a primary metabolite of the highly selective COX-2 inhibitor valdecoxib-was synthesized and stabilized as its monohydrate (3a.H(2)O). valdecoxib 128-138 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 17661262-1 2007 Concerning the current discussion about cardiovascular toxicity of the selective COX-2 inhibitors, recently advertised in the media as a new milestone in the management of pain, culminating in the market withdrawal of the preparations Vioxx (rofecoxib) in 2004 and Bextra (valdecoxib) in 2005, the classical NSAIDs are now spotlighted. valdecoxib 265-271 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 17661262-1 2007 Concerning the current discussion about cardiovascular toxicity of the selective COX-2 inhibitors, recently advertised in the media as a new milestone in the management of pain, culminating in the market withdrawal of the preparations Vioxx (rofecoxib) in 2004 and Bextra (valdecoxib) in 2005, the classical NSAIDs are now spotlighted. valdecoxib 273-283 mitochondrially encoded cytochrome c oxidase II Homo sapiens 81-86 17305573-9 2007 Recently, some COX-2 selective inhibitors have shown adverse cardiovascular side effects, resulting in the withdrawal of rofecoxib and valdecoxib from the market. valdecoxib 135-145 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 17525166-0 2007 Utility and sensitivity of the sore throat pain model: results of a randomized controlled trial on the COX-2 selective inhibitor valdecoxib. valdecoxib 129-139 mitochondrially encoded cytochrome c oxidase II Homo sapiens 103-108 19075973-10 2007 Moreover, we will discuss recent patents of structural analogs of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole, thione derivatives as a future target for the treatment of inflammation, pain and other diseases. valdecoxib 101-111 mitochondrially encoded cytochrome c oxidase II Homo sapiens 70-75 17397743-1 2007 PURPOSE: To evaluate the safety and efficacy of the COX-2 inhibitor valdecoxib in treating macular edema after cataract surgery. valdecoxib 68-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 52-57 17397743-3 2007 METHODS: The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial. valdecoxib 29-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 17397743-3 2007 METHODS: The COX-2 inhibitor valdecoxib (Bextra) was administered systemically to patients with significant visual loss resulting from macular edema in a prospective clinical trial. valdecoxib 41-47 mitochondrially encoded cytochrome c oxidase II Homo sapiens 13-18 16529650-2 2006 This study aimed to investigate the efficacy of a single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization - induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers. valdecoxib 100-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 84-89 17504133-5 2007 Initially described as COX-2 "selective" inhibitors, recent reports revealed a nanomolar inhibition activity of the sulfonamide COX-2 inhibitors for several carbonic anhydrase (CA) isoforms, confirmed by X-ray crystal structures for the adducts of celecoxib and valdecoxib with isozyme CA II. valdecoxib 262-272 mitochondrially encoded cytochrome c oxidase II Homo sapiens 128-133 16476920-0 2006 The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial. valdecoxib 29-39 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 16618816-2 2006 Whether the newer second-generation COX-2 inhibitors (etoricoxib, valdecoxib) also increase the cardiovascular risk is unknown. valdecoxib 66-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. valdecoxib 260-266 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 16519515-1 2006 The two cyclooxygenase enzymes, COX-1 and COX-2, are responsible for the committed step in prostaglandin biosynthesis and are the targets of the nonsteroidal antiinflammatory drugs aspirin and ibuprofen and the COX-2 selective inhibitors, Celebrex, Vioxx, and Bextra. valdecoxib 260-266 mitochondrially encoded cytochrome c oxidase II Homo sapiens 211-216 16178945-2 2005 BACKGROUND: Valdecoxib, an oral COX-2 specific inhibitor, is indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis and treatment of primary dysmenorrhea. valdecoxib 12-22 mitochondrially encoded cytochrome c oxidase II Homo sapiens 32-37 16599270-1 2006 A simple, sensitive, isocratic and reproducible reversed phase HPLC method for the determination of valdecoxib, a novel specific COX-2 inhibitor in human serum was developed using a diode array detector and celecoxib as internal standard. valdecoxib 100-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 129-134 16311613-1 2005 OBJECTIVE: To determine the risk of serious cardiovascular events associated with the use of the COX-2 inhibitor valdecoxib and its prodrug parecoxib following major surgery. valdecoxib 113-123 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 16083531-5 2005 Highly selective COX-2 inhibitors including celecoxib, rofecoxib, valdecoxib, lumiracoxib, and etoricoxib were developed with the hope of significantly reducing the serious gastrointestinal toxicities associated with chronic high-dose NSAID use. valdecoxib 66-76 mitochondrially encoded cytochrome c oxidase II Homo sapiens 17-22 15887009-0 2005 The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. valdecoxib 78-88 mitochondrially encoded cytochrome c oxidase II Homo sapiens 102-107 15494548-3 2005 We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. valdecoxib 84-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 15713945-0 2005 Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. valdecoxib 52-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 15494548-3 2005 We report here the pharmacological properties of a third selective COX-2 inhibitor, valdecoxib, which is the most potent and in vitro selective of the marketed COX-2 inhibitors that we have studied. valdecoxib 84-94 mitochondrially encoded cytochrome c oxidase II Homo sapiens 160-165 15494548-5 2005 Valdecoxib potently inhibits recombinant COX-2, with an IC(50) of 0.005 microM; this compares with IC values of 0.05 microM for celecoxib, 0.5 microM for rofecoxib, and 5 microM for etoricoxib. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 41-46 15494548-6 2005 Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). valdecoxib 31-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 47-52 15494548-6 2005 Unique binding interactions of valdecoxib with COX-2 translate into a fast rate of inactivation of COX-2 (110,000 M/s compared with 7000 M/s for rofecoxib and 80 M/s for etoricoxib). valdecoxib 31-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 99-104 15494548-7 2005 The overall saturation binding affinity for COX-2 of valdecoxib is 2.6 nM (compared with 1.6 nM for celecoxib, 51 nM for rofecoxib, and 260 nM for etoricoxib), with a slow off-rate (t(1/2) approximately 98 min). valdecoxib 53-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 44-49 15494548-9 2005 Collectively, these data provide a mechanistic basis for the potency and in vitro selectivity of valdecoxib for COX-2. valdecoxib 97-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 112-117 15494548-10 2005 Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM). valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 71-76 15974940-5 2005 COX-2-selective inhibitors (Coxibs) such as celecoxib, rofecoxib or valdecoxib have been developed to achieve an equal relief of pain and inflammation as classical NSAIDs but without their risk of gastrointestinal side effects. valdecoxib 68-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 0-5 15641602-0 2004 [The specific cox-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery]. valdecoxib 30-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 16180941-3 2005 OBJECTIVE: The objective of this study is to review cases of Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the FDA associated with the use of the selective COX-2 inhibitor NSAIDs celecoxib, rofecoxib and valdecoxib, and to compare reporting rates of the two conditions associated with these drugs to each other, meloxicam (an oxicam NSAID that came on the US market at a similar time) and the background incidence rate. valdecoxib 226-236 mitochondrially encoded cytochrome c oxidase II Homo sapiens 178-183 16180941-10 2005 CONCLUSION: There is a strong association between Stevens-Johnson syndrome/toxic epidermal necrolysis and the use of the sulfonamide COX-2 inhibitors, particularly valdecoxib. valdecoxib 164-174 mitochondrially encoded cytochrome c oxidase II Homo sapiens 133-138 15279596-2 2004 A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the COX-2 selective inhibitors, with at least two clinically used drugs, celecoxib and valdecoxib. valdecoxib 217-227 mitochondrially encoded cytochrome c oxidase II Homo sapiens 134-139 15339324-0 2004 Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. valdecoxib 100-110 mitochondrially encoded cytochrome c oxidase II Homo sapiens 73-78 15039937-1 2004 Valdecoxib is a potent COX-2 inhibitor. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-28 15279595-1 2004 Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 95-100 15050982-4 2004 In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. valdecoxib 79-89 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 15050982-4 2004 In vivo studies have found the specific COX-2 inhibitors rofecoxib (Vioxx) and valdecoxib (Bextra) effective in treatment of primary dysmenorrhea in women >or=18 years. valdecoxib 91-97 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 15182039-1 2004 Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 15182039-1 2004 Valdecoxib (Bextra tablets of 10 mg and 20 mg) is a new non steroidal antiinflammatory drug (NSAID) that selectively inhibits COX-2 isoform of cyclo-oxygenase. valdecoxib 12-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 126-131 15266215-2 2004 We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. valdecoxib 43-53 mitochondrially encoded cytochrome c oxidase II Homo sapiens 61-66 15117884-2 2004 Selective inhibitors of COX-2, such as celecoxib, etoricoxib, lumiracoxib, rofecoxib, and valdecoxib have been developed and the greatest recent growth in our knowledge in this area has been come from the clinical use of these compounds. valdecoxib 90-100 mitochondrially encoded cytochrome c oxidase II Homo sapiens 24-29 14698154-3 2004 Sulpiride shows CA inhibitory properties of the same magnitude as dichlorophenamide, a clinically used antiglaucoma sulfonamide, or valdecoxib, a COX-2 selective inhibitor recently shown to inhibit CA. valdecoxib 132-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 146-151 14965322-1 2004 Novel coxibs (i.e. etoricoxib, valdecoxib, parecoxib and lumiracoxib) with enhanced biochemical cyclooxygenase (COX)-2 selectivity over that of rofecoxib and celecoxib have been recently developed. valdecoxib 31-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 96-118 15124935-5 2004 Selective COX-2 inhibitors currently used in the clinic are the sulphonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulphones rofecoxib and etoricoxib. valdecoxib 92-102 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15161329-1 2004 Valdecoxib is an orally administered, highly selective cyclo-oxygenase (COX)-2 inhibitor with anti-inflammatory and analgesic properties. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 55-78 15161329-14 2004 In conclusion, valdecoxib, a COX-2-selective inhibitor, is as efficacious in pain relief as nonselective NSAIDs, with better gastrointestinal tolerability. valdecoxib 15-25 mitochondrially encoded cytochrome c oxidase II Homo sapiens 29-34 15124935-5 2004 Selective COX-2 inhibitors currently used in the clinic are the sulphonamides celecoxib and valdecoxib (parecoxib is a prodrug of valdecoxib), as well as the methylsulphones rofecoxib and etoricoxib. valdecoxib 130-140 mitochondrially encoded cytochrome c oxidase II Homo sapiens 10-15 15198407-1 2003 Valdecoxib, a COX-2 inhibitor, has recently been introduced as a gel formulation. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 14655004-2 2003 Currently, there are four selective COX-2 inhibitors available in Germany: celecoxib, rofecoxib, valdecoxib and parecoxib. valdecoxib 97-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 36-41 14748383-1 2003 Parecoxib, a prodrug of valdecoxib, a selective COX-2 inhibitor, has been recently introduced for the treatment of moderate to severe postoperative pain. valdecoxib 24-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 48-53 14585916-5 2003 In comparative trials of celecoxib or valdecoxib with non-specific NSAIDs, COX-2-specific inhibitors were demonstrated to have superior dyspepsia tolerability than non-specific NSAIDs. valdecoxib 38-48 mitochondrially encoded cytochrome c oxidase II Homo sapiens 75-80 14552704-5 2003 Recently, other selective COX-2 inhibitors with different COX-1/COX-2 selectivity and pharmacokinetic features have been developed, i.e. valdecoxib, parecoxib, etoricoxib and lumiracoxib. valdecoxib 137-147 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 14552704-6 2003 The improved biochemical selectivity of valdecoxib vs celecoxib in vitro (COX-1/COX-2 ratio: 60 vs 30, respectively) may be clinically relevant leading to an improved GI safety. valdecoxib 40-50 mitochondrially encoded cytochrome c oxidase II Homo sapiens 80-85 12751271-0 2003 The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. valdecoxib 31-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 12751271-1 2003 The effects of the new cyclooxygenase (COX)-2 selective inhibitor, valdecoxib (40 mg bid; n = 17), on platelet function were evaluated, along with ibuprofen (800 mg tid; n = 15) and placebo (n = 15), in healthy elderly subjects (65-85 years) in this 7.5-day, randomized, single-center, double-blind study. valdecoxib 67-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 23-45 12644588-5 2003 The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 x 10(6)/M/min and 4.5 x 10(6)/M/min and dissociation rates of 14 x 10(-3)/min (t(1/2) = 50 min) and 7.0 x 10(-3)/min (t(1/2) = 98 min) for [(3)H]celecoxib and [(3)H]valdecoxib, respectively. valdecoxib 261-271 mitochondrially encoded cytochrome c oxidase II Homo sapiens 15-20 12644588-9 2003 These binding studies provide direct insight into the properties and binding constants of celecoxib and valdecoxib to COX-2. valdecoxib 104-114 mitochondrially encoded cytochrome c oxidase II Homo sapiens 118-123 12868201-3 2003 Slow, time-dependent, irreversible, highly selective inhibitors of COX-2 such as celecoxib, etoricoxib, rofecoxib and valdecoxib, so-called coxibs, are a new group of drugs widely used in rheumatology as well as in other fields of medicine. valdecoxib 118-128 mitochondrially encoded cytochrome c oxidase II Homo sapiens 67-72 12852704-4 2003 OBJECTIVE: This article reviews available information on the new COX-2-selective inhibitor valdecoxib, including its clinical pharmacology, pharmacokinetics, adverse effects, potential drug interactions, and contraindications and warnings. valdecoxib 91-101 mitochondrially encoded cytochrome c oxidase II Homo sapiens 65-70 12852704-19 2003 As with the other COX-2-selective inhibitors (celecoxib and rofecoxib), valdecoxib appears to produce less gastrointestinal toxicity than conventional nonselective NSAIDs, although some of the relevant clinical studies have been published only as abstracts. valdecoxib 72-82 mitochondrially encoded cytochrome c oxidase II Homo sapiens 18-23 12562317-1 2003 The development of COX2 inhibitors with improved biochemical selectivity (such as etoricoxib and valdecoxib) over that of commercially available coxibs has been driven by the potential advantage of safety using higher coxib doses for increased efficacy. valdecoxib 97-107 mitochondrially encoded cytochrome c oxidase II Homo sapiens 19-23 12590029-0 2003 The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. valdecoxib 30-40 mitochondrially encoded cytochrome c oxidase II Homo sapiens 4-9 12590029-1 2003 This multicenter, randomized, double-blind, placebo-controlled study evaluated the analgesic efficacy and opioid-sparing effects of valdecoxib, a potent COX-2 specific inhibitor, in patients undergoing knee replacement. valdecoxib 132-142 mitochondrially encoded cytochrome c oxidase II Homo sapiens 153-158 10715145-0 2000 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. valdecoxib 56-66 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. valdecoxib 203-213 mitochondrially encoded cytochrome c oxidase II Homo sapiens 60-65 12629931-1 2003 The discovery of the isoenzymes cyclooxygenase-(COX-) 1 and COX-2 led to the development of newer nonsteroidal anti-inflammatory drugs (NSAIDs) designed to block COX-2, such as rofecoxib, celecoxib, and valdecoxib. valdecoxib 203-213 mitochondrially encoded cytochrome c oxidase II Homo sapiens 162-167 12797647-1 2002 Valdecoxib, a COX-2 inhibitor, has been introduced as a new treatment for osteo-arthritis (OA). valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 14-19 12209034-1 2002 OBJECTIVE: To compare the efficacy of the COX-2 specific inhibitor valdecoxib with the conventional NSAID naproxen and placebo in treating rheumatoid arthritis (RA). valdecoxib 67-77 mitochondrially encoded cytochrome c oxidase II Homo sapiens 42-47 12227215-1 2002 Valdecoxib is a selective COX-2 inhibitor that is similar in anti-inflammatory activity to the other selective COX-2 inhibitors (e.g., celecoxib and rofecoxib). valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 26-31 11981510-0 2002 Valdecoxib (Bextra)--a new cox-2 inhibitor. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11981510-0 2002 Valdecoxib (Bextra)--a new cox-2 inhibitor. valdecoxib 12-18 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 12020053-1 2002 Pharmacia (formerly Searle), in collaboration with Pfizer and Yamanouchi, has developed valdecoxib, a second-generation cyclooxygenase (COX)-2 inhibitor as a follow-up to celecoxib, for the treatment of arthritis. valdecoxib 88-98 mitochondrially encoded cytochrome c oxidase II Homo sapiens 136-142 12020053-5 2002 The company claims that valdecoxib has improved potency and broader therapeutic range than other COX-2 inhibitors including celecoxib, and has the potential for once-daily dosing [287279], [313957]. valdecoxib 24-34 mitochondrially encoded cytochrome c oxidase II Homo sapiens 97-102 12020053-7 2002 Valdecoxib has been described by Searle as almost superimposable at the site critical for COX-2 inhibition, a structural side pocket in the enzyme which coincides with the sulfonamide group of the drug [324667]. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 90-95 11060833-1 2000 Parecoxib is a prodrug of valdecoxib, which is a potent and selective inhibitor of COX-2. valdecoxib 26-36 mitochondrially encoded cytochrome c oxidase II Homo sapiens 83-88 10715145-0 2000 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. valdecoxib 0-54 mitochondrially encoded cytochrome c oxidase II Homo sapiens 104-109 12198983-6 2002 (The other selective COX-2 inhibitors, celecoxib and valdecoxib, do not carry label indications for short-term management of postoperative pain.) valdecoxib 53-63 mitochondrially encoded cytochrome c oxidase II Homo sapiens 21-26 12036167-11 2002 The studies reported here suggest that the COX-2-specific inhibitor valdecoxib offers an efficacious and safe alternative to other analgesics used to treat pain after oral surgery. valdecoxib 68-78 mitochondrially encoded cytochrome c oxidase II Homo sapiens 43-48 11950252-0 2002 Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. valdecoxib 52-62 mitochondrially encoded cytochrome c oxidase II Homo sapiens 27-32 11950252-2 2002 This study compared the efficacy of the COX-2 specific inhibitor valdecoxib with naproxen and placebo, in treating symptomatic OA of the hip. valdecoxib 65-75 mitochondrially encoded cytochrome c oxidase II Homo sapiens 40-45 11897923-2 2002 Valdecoxib is a new highly selective COX-2 inhibitor with a rapid onset of action and significant analgesic properties. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 37-42 12564662-3 2002 Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 74-79 12564662-3 2002 Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively. valdecoxib 0-10 mitochondrially encoded cytochrome c oxidase II Homo sapiens 105-110